Roche’s Skin Cancer Treatment Delayed by U.K. Drug-Cost A

Roche Holding AG will have to provide more information about the expense of the Zelboraf skin-cancer treatment before the U.K.’s drug-cost agency will decide whether to recommend use in the National Health Service.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.